SCHEMBL4070529

SCHEMBL4070529

Cc1ccc(S(=O)(=O)/C(C#N)=C\c2cc(C(C)(C)C)c(O)c(C(C)(C)C)c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.57
PKM P14618 3/20 0.57
ALDH1A1 P00352 8/20 0.52
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
MAPT P10636 6/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
HSD17B10 Q99714 4/20 0.52
LMNA P02545 4/20 0.52
ALOX15 P16050 3/20 0.52
CYP3A4 P08684 3/20 0.52
TSHR P16473 3/20 0.52
BLM P54132 3/20 0.52
RECQL P46063 3/20 0.52
GAA P10253 3/20 0.52
RGS12 O14924 2/20 0.52
GMNN O75496 2/20 0.52
TP53 P04637 2/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2C9 P11712 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4070530 1.00 HPGD (0.57) HPGDPKMALDH1A1MEN1KMT2A
SCHEMBL4071014 0.90 HPGD (0.52) HPGDPKMALDH1A1MEN1KMT2A
SCHEMBL4071011 0.90 HPGD (0.52) HPGDPKMALDH1A1MEN1KMT2A
SCHEMBL4070167 0.90 HPGD (0.52) HPGDPKMALDH1A1MEN1KMT2A
SCHEMBL4070166 0.90 HPGD (0.52) HPGDPKMALDH1A1MEN1KMT2A
SCHEMBL4071042 0.89 HPGD (0.51) HPGDPKMALDH1A1MEN1KMT2A
SCHEMBL3242402 0.89 KMT2A (0.51) HPGDPKMALDH1A1MEN1KMT2A
SCHEMBL3242400 0.89 KMT2A (0.51) HPGDPKMALDH1A1MEN1KMT2A
SCHEMBL4071041 0.89 HPGD (0.51) HPGDPKMALDH1A1MEN1KMT2A
SCHEMBL4073187 0.89 HPGD (0.51) HPGDPKMALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1625112-B1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY HIGH POINT PHARMACEUTICALS LLC (US) 2009-07-22 EP claimed
JP-2007503453-A 2007-02-22 JP claimed
US-20060128662-A1 Novel compounds for treatment of obesity NOVO NORDISK A/S (DK) 2006-06-15 US claimed
EP-1625112-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2006-02-15 EP claimed
WO-2004101505-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2004-11-25 WO claimed
EP-1625112-B1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY HIGH POINT PHARMACEUTICALS LLC (US) 2009-07-22 EP disclosed
US-20060128662-A1 Novel compounds for treatment of obesity NOVO NORDISK A/S (DK) 2006-06-15 US disclosed
EP-1625112-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2006-02-15 EP disclosed
WO-2004101505-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128662-A1 Novel compounds for treatment of obesity GPR119, FABP4, HSD17B4 HPGD 692/4885PKM 1478/4885ALDH1A1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.